Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGRX Agile Therapeutics	$1.51	$1.49	$0.20 ▼ $2.63	$10.35M	1.58	352,864 shs	120,938 shs
AKTX Akari Therapeutics	$1.35 -4.6%	$1.27	$0.85 ▼ $4.40	$43.44M	0.29	31,854 shs	10,466 shs
AVTX Avalo Therapeutics	$4.40 +1.1%	$4.90	$3.39 ▼ $16.00	$47.64M	0.87	54,997 shs	69,357 shs
KPTI Karyopharm Therapeutics	$4.25 +3.2%	$5.01	$3.51 ▼ $17.40	$36.72M	0.33	82,215 shs	82,948 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGRX Agile Therapeutics	0.00%	0.00%	0.00%	0.00%	+318.28%
AKTX Akari Therapeutics	+8.85%	+10.98%	+2.54%	+50.53%	-17.44%
AVTX Avalo Therapeutics	+10.13%	+16.00%	-13.69%	-36.96%	-62.77%
KPTI Karyopharm Therapeutics	-4.19%	-10.24%	-44.02%	-35.32%	-71.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGRX Agile Therapeutics	0.1254 of 5 stars	0.0	0.0	0.0	4.0	0.0	0.0	0.0
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	2.9807 of 5 stars	3.5	3.0	0.0	0.0	2.6	1.7	1.3
KPTI Karyopharm Therapeutics	3.7901 of 5 stars	3.5	0.0	0.0	4.6	2.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGRX Agile Therapeutics	0.00	N/A	N/A	N/A
AKTX Akari Therapeutics	0.00	N/A	N/A	N/A
AVTX Avalo Therapeutics	3.00	Buy	$30.00	581.82% Upside
KPTI Karyopharm Therapeutics	3.00	Buy	$43.20	916.47% Upside

Current Analyst Ratings Breakdown

Latest AGRX, AKTX, AVTX, and KPTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$15.00
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00
3/25/2025	AVTX Avalo Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform ➝ Buy	$23.00
3/25/2025	AVTX Avalo Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$36.00
3/20/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/20/2025	AVTX Avalo Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$18.00
3/3/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$75.00 ➝ $54.00

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGRX Agile Therapeutics	$19.98M	0.52	N/A	N/A	($5.51) per share	-0.27
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	($0.03) per share	N/A
AVTX Avalo Therapeutics	$441K	108.03	N/A	N/A	$9.11 per share	0.48
KPTI Karyopharm Therapeutics	$142.13M	0.26	N/A	N/A	($1.47) per share	-2.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGRX Agile Therapeutics	-$14.47M	-$3.65	N/A	∞	N/A	-36.24%	N/A	-147.37%	N/A
AKTX Akari Therapeutics	-$10.01M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/18/2025 (Estimated)
AVTX Avalo Therapeutics	-$31.54M	N/A	0.00	N/A	N/A	N/A	-442.16%	122.99%	8/11/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$143.10M	-$13.26	N/A	N/A	N/A	-52.62%	N/A	-39.58%	8/5/2025 (Estimated)

Latest AGRX, AKTX, AVTX, and KPTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/12/2025	Q1 2025	AVTX Avalo Therapeutics	-$1.07	-$1.25	-$0.18	-$1.25	N/A	N/A
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGRX Agile Therapeutics	N/A	N/A	N/A	N/A	N/A
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGRX Agile Therapeutics	N/A	0.56	0.38
AKTX Akari Therapeutics	N/A	0.29	0.29
AVTX Avalo Therapeutics	N/A	1.42	1.42
KPTI Karyopharm Therapeutics	N/A	1.70	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGRX Agile Therapeutics	10.92%
AKTX Akari Therapeutics	5.06%
AVTX Avalo Therapeutics	87.06%
KPTI Karyopharm Therapeutics	66.44%

Insider Ownership

Company	Insider Ownership
AGRX Agile Therapeutics	0.50%
AKTX Akari Therapeutics	38.90%
AVTX Avalo Therapeutics	3.03%
KPTI Karyopharm Therapeutics	2.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGRX Agile Therapeutics	30	6.86 million	6.82 million	Not Optionable
AKTX Akari Therapeutics	9	32.18 million	16.25 million	Not Optionable
AVTX Avalo Therapeutics	40	10.83 million	10.37 million	Not Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	122.72 million	Optionable

AGRX, AKTX, AVTX, and KPTI Headlines

Recent News About These Companies

Karyopharm to Present at the Jefferies Global Healthcare Conference

June 3 at 8:00 AM | prnewswire.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2 at 4:05 PM | prnewswire.com

Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now

May 26, 2025 | zacks.com

Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?

May 19, 2025 | zacks.com

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

May 19, 2025 | prnewswire.com

Robert W. Baird Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price

May 15, 2025 | marketbeat.com

Karyopharm Therapeutics (NASDAQ:KPTI) Posts Earnings Results, Beats Estimates By $1.44 EPS

May 14, 2025 | marketbeat.com

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

May 14, 2025 | prnewswire.com

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

May 12, 2025 | zacks.com

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

May 12, 2025 | prnewswire.com

Karyopharm Therapeutics (KPTI) to Release Earnings on Wednesday

May 9, 2025 | marketbeat.com

Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Below 200 Day Moving Average - Here's Why

May 9, 2025 | marketbeat.com

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

May 8, 2025 | prnewswire.com

Why Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Down 5.15%

May 6, 2025 | aaii.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2025 | prnewswire.com

Karyopharm Therapeutics Inc.DL-Exch. Notes 2018(25) Bond

May 1, 2025 | markets.businessinsider.com

Why Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Up 5.06%

April 30, 2025 | aaii.com

Karyopharm Therapeutics Inc. Common Stock (KPTI)

April 23, 2025 | nasdaq.com

Karyopharm Therapeutics Inc. Common Stock (KPTI)

April 23, 2025 | nasdaq.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 1, 2025 | prnewswire.com

Karyopharm price target lowered to split-adjusted $15 from $75 at Piper Sandler

March 20, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGRX, AKTX, AVTX, and KPTI Company Descriptions

Agile Therapeutics NASDAQ:AGRX

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Akari Therapeutics NASDAQ:AKTX

$1.35 -0.07 (-4.59%)

Closing price 03:50 PM Eastern

Extended Trading

$1.34 -0.01 (-0.37%)

As of 04:04 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Avalo Therapeutics NASDAQ:AVTX

$4.40 +0.05 (+1.15%)

Closing price 04:00 PM Eastern

Extended Trading

$4.40 0.00 (0.00%)

As of 04:04 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Karyopharm Therapeutics NASDAQ:KPTI

$4.25 +0.13 (+3.16%)

Closing price 04:00 PM Eastern

Extended Trading

$4.24 -0.01 (-0.26%)

As of 05:31 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time